FWD Life Insurance collaborates with Roche Diagnostics to promote preventive health care in the FWD HealthyMe - Liver Health Programme for liver cancer screening

Press Releases »

FWD Life Insurance Plc. ("FWD Insurance") announced its strategic collaboration with Roche Diagnostics (Thailand) Ltd., or "Roche," in the FWD HealthyMe - Liver Health Programme. This is the first project in the life insurance industry to introduce diagnostic aids in the early stages of HCC (Hepatocellular Carcinoma) through blood-based tumour markers and GAAD, Roche's Digital Medical Algorithm and an FDA Thailand-approved, for the detection of early-stage liver cancer in at-risk individuals for customers holding FWD Precious Care and FWD Exclusive Care health insurance policies who meet the company's criteria and conditions, at no cost. This program aims to promote preventive health care from the beginning and is available at three partner hospitals: Nakornthon Hospital, Piyavate Hospital, and Samitivej Sukhumvit Hospital.

FWD Life Insurance collaborates with Roche Diagnostics to promote preventive health care in the FWD HealthyMe - Liver Health Programme for liver cancer screening

The FWD HealthyMe - Liver Health Programme aims to develop collaboration with healthcare providers and industry leaders to become partners in proactive health care. This cooperation reflects FWD Life Insurance's commitment to enhancing its services to cover all health dimensions, being a health partner for customers through effective preventive health care methods and providing customers with confidence in living their lives.

FWD Life Insurance collaborates with Roche Diagnostics to promote preventive health care in the FWD HealthyMe - Liver Health Programme for liver cancer screening

FWD Life Insurance Plc. ("FWD Insurance") announced its strategic collaboration with Roche Diagnostics (Thailand) Ltd., or "Roche," in the FWD HealthyMe - Liver Health Programme. This is the first project in the life insurance industry to introduce diagnostic aids in the early stages of HCC (Hepatocellular Carcinoma) through blood-based tumour markers and GAAD, Roche's Digital Medical Algorithm and an FDA Thailand-approved, for the detection of early-stage liver cancer in at-risk individuals for customers holding FWD Precious Care and FWD Exclusive Care health insurance policies who meet the company's criteria and conditions, at no cost. This program aims to promote preventive health care from the beginning and is available at three partner hospitals: Nakornthon Hospital, Piyavate Hospital, and Samitivej Sukhumvit Hospital.

The FWD HealthyMe - Liver Health Programme aims to develop collaboration with healthcare providers and industry leaders to become partners in proactive health care. This cooperation reflects FWD Life Insurance's commitment to enhancing its services to cover all health dimensions, being a health partner for customers through effective preventive health care methods and providing customers with confidence in living their lives.


ข่าวHepatocellular Carcinoma+o:editorวันนี้

Bangchak Partners with Noovoleum to Launch Ucollect Box Pilot to Collect Used Cooking Oil for SAF Production

Bangchak Corporation Public Company Limited, represented by Mrs. Narupan Suthamkasem, Senior Executive Vice President, Corporate Strategy and Business Development, signed a Framework Agreement on Collaboration for the Ucollect Box Pilot with Mr. Philippe Micone, Founder and Chief Executive Officer of Noovoleum, a technology partner company from Indonesia. The Ucollect Box is an automated used cooking oil collection service unit to be processed into sustainable aviation fuel (SAF). The signing

JW Therapeutics Announces Initiation of Clinical Study of JWATM204 in Patients with Advanced Hepatocellular Carcinoma

JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the...

“SIRveNIB” โครงการวิจัยโรคมะเร็งตับปฐมภูมิในเอเชียแปซิฟิก เสร็จสิ้นการรับสมัครผู้ป่วยเข้าร่วมการวิจัยแล้ว

การวิจัยแบบสุ่มและมีกลุ่มควบคุมเพื่อเปรียบเทียบประสิทธิภาพระหว่าง Sorafenib กับ SIR-Spheres(R) Y-90 resin microspheres ในการรักษาโรคมะเร็งตับชนิด Hepatocellular Carcinoma แบบผ่าตัดไม่ได้ ของกลุ่ม...

SIRveNIB, a Major Primary Liver Cancer Study in the Asia-Pacific Region, Completes Enrolment

Results of Asia-Pacific Hepatocellular Carcinoma Trials Group (AHCC) Randomised Controlled Study Comparing Sorafenib and SIR-Spheres(R) Y-90 resin microspheres in the Treatment of Unresectable Hepatocellular...

รายงาน Medtech Innovation Briefing ฉบับล่าสุดจากสถาบัน UK NICE ยกให้ SIR-Spheres(R) Y-90 Resin Microspheres เป็นอีกหนึ่งทางเลือกที่ผู้ป่วยสามารถทนต่อยาได้ดี

Sirtex (ASX: SRX) ประกาศในวันนี้ว่า สถาบันเพื่อความเป็นเลิศด้านสุขภาพและการบริบาลแห่งสหราชอาณาจักร (NICE) ได้เผยแพร่รายงาน Medtech Innovation...